Cureus · 2024
Relationship Between Sexual Dysfunction and Quality of Life in Psychiatric Patients Receiving Regular Treatment: A Cross-Sectional Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Damam Siva Prasad, Yeshala Veerabadram, Mukkara Ramasubba Reddy, Boorla Vivaswan, Kotha Rakesh
Аннотация
BACKGROUND: Sexual dysfunction (SD) is a significant issue among psychiatric patients on psychotropic medications. This study aims to compare SD in patients using antipsychotics and antidepressants.
OBJECTIVE: To evaluate the prevalence of SD and its effect on the quality of life among psychiatric patients on medications.
METHODS: A cross-sectional study had been conducted with 150 participants (50 with schizophrenia, 50 with affective disorders, and 50 controls). SD was evaluated employing the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) and the Arizona Sexual Experience Scale (ASEX). The Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) was used to measure the quality of life. Data analysis techniques included Spearman's correlation test, one-way ANOVA, chi-square test, and descriptive statistics.
RESULTS: SD prevalence was 42% in affective disorders, 64% in schizophrenia, and 18% in controls. SD significantly correlated with a longer duration of psychotropic use and negatively impacted quality of life.
CONCLUSION: SD is prevalent among psychiatric patients on long-term medication, highlighting the need for strategies to manage these side effects.
OBJECTIVE: To evaluate the prevalence of SD and its effect on the quality of life among psychiatric patients on medications.
METHODS: A cross-sectional study had been conducted with 150 participants (50 with schizophrenia, 50 with affective disorders, and 50 controls). SD was evaluated employing the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) and the Arizona Sexual Experience Scale (ASEX). The Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) was used to measure the quality of life. Data analysis techniques included Spearman's correlation test, one-way ANOVA, chi-square test, and descriptive statistics.
RESULTS: SD prevalence was 42% in affective disorders, 64% in schizophrenia, and 18% in controls. SD significantly correlated with a longer duration of psychotropic use and negatively impacted quality of life.
CONCLUSION: SD is prevalent among psychiatric patients on long-term medication, highlighting the need for strategies to manage these side effects.